Back

Evolution of resistance to KRASG12C inhibitor in a non-small cell lung cancer responder

Xu, J.; Wang, S.; Wang, Z.; Huang, J.; Xie, C.; Cao, Y.; Ming, C.; Leung, E. L.-H.

2023-12-20 cancer biology
10.1101/2023.12.18.572090 bioRxiv
Show abstract

Despite initial therapeutic successes, most patients with non-small cell lung cancer (NSCLC) who carry the KRASG12C mutation ultimately exhibit resistance to targeted treatments. To improve our comprehension of how acquired resistance develops, we present an unprecedented longitudinal case study profiling the transcriptome of peripheral blood mononuclear cells (PBMCs) over 5 months from an NSCLC patient with the KRASG12C mutation and initial response to sotorasib followed by resistance and death. Single-cell RNA sequencing analysis uncovered notable fluctuations in immune cell populations throughout treatment with sotorasib. Specifically, we observed a decline in circulating CD8+CD161hi T cells correlating with periods of therapeutic response, followed by a resurgence during phases of nonresponse. This study established a high-resolution atlas detailing the evolutionary trajectory of resistance to sotorasib and characterizes a CD8+CD161hi T cells population in KRASG12C mutation patient.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.